[1. Zemin C, EC. M. Pathogenesis of diabetic nephropathy. J Diabetes Invest 2011;2:243-7.10.1111/j.2040-1124.2011.00131.x401496024843491]Search in Google Scholar
[2. Fard AA, Abbasnezhad P, Makhdomi K, et al. Association of Serum Prolactin Concentrations with Renal Failure in Diabetic Patients. Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2017;24(3):179-85.10.1515/rjdnmd-2017-0023]Search in Google Scholar
[3. Ibrahim HN, TH. H. Diabetic nephropathy. J Am Soc Nephrol. 1997;8:487-93.10.1681/ASN.V834879071718]Search in Google Scholar
[4. Atkins R, Zimmet PI-I. World Kidney Day Steering Committee: Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol. 2010;6:134-6.10.1038/nrneph.2010.1020186229]Search in Google Scholar
[5. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271(17):10079-86.10.1074/jbc.271.17.100798626565]Search in Google Scholar
[6. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nature medicine. 1998;4(6):691-7.10.1038/nm0698-6919623978]Search in Google Scholar
[7. Makino H, Ikeda S, Haramoto T, Ota Z. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Nephron. 1992;61(4):415-21.10.1159/0001869591501738]Search in Google Scholar
[8. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proceedings of the National Academy of Sciences. 1979;76(3):1303-7.10.1073/pnas.76.3.1303383239155819]Search in Google Scholar
[9. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PloS one. 2011;6(2):e17312.10.1371/journal.pone.0017312304309821364956]Search in Google Scholar
[10. Rops AL, Van den Hoven MJ, Veldman BA, et al. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrology Dialysis Transplantation. 2012;27(7):2853-61.10.1093/ndt/gfr73222187315]Search in Google Scholar
[11. Rosenzweig L, Kanwar Y. Removal of sulfated (heparan sul-fate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest. 1982;47(2):177-84.]Search in Google Scholar
[12. Kolset S, Reinholt F, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60(12):976-86.10.1369/0022155412465073]Search in Google Scholar
[13. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovascular Therapeutics. 2006;24(3-4):214-26.10.1111/j.1527-3466.2006.00214.x]Search in Google Scholar
[14. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide. Med Res Rev. 1998;18(1):1-20.10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4]Search in Google Scholar
[15. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1997;12(11):2295-300.10.1093/ndt/12.11.2295]Search in Google Scholar
[16. Skrha J, Perusicová J, Pont’uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25-31.10.1016/S0168-8227(97)00076-4]Search in Google Scholar
[17. Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kid Dis,2011;58(5):729-36.10.1053/j.ajkd.2011.06.020]Search in Google Scholar
[18. Reddi AS, Ramamurti R, Miller M, et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol. 1991;45(119-131).10.1016/0885-4505(91)90014-C]Search in Google Scholar
[19. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes. 2007;56(7):1825-33.10.2337/db06-1226]Search in Google Scholar
[20. Brosius FC, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-12.10.1681/ASN.2009070721]Search in Google Scholar
[21. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev. 2001;17(6):412-21.10.1002/dmrr.236]Search in Google Scholar
[22. Vanden Born J, Van Kraats AA, Hill S, et al. Vessel wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in the rat. Nephrol Dial Transplant. 1997;12(2):27-31.]Search in Google Scholar
[23. De Lima CR, Aguiar JA, Michelacci YM. Reduced urinary excretion of sulfated polysaccharides in diabetic rats. Biochim Biophys Acta.2005;1741(1-2):30-41.10.1016/j.bbadis.2004.10.001]Search in Google Scholar
[24. Cadaval RA, Kohlman O, Michelacci YM. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology. 2000;10(2):185-92.10.1093/glycob/10.2.185]Search in Google Scholar
[25. Yavuz DG, Ersöz HO, Tuncel M et al. Effects of Aminoguanidine on Glomerular Basement Membrane Thickness and Anionic Charge in a Diabetic Rat Model. Int Jnl Experimental Diab Res. 2001;2:225-32.10.1155/EDR.2001.225]Search in Google Scholar
[26. McAuliffe A, Fisher E, McLennan S, et al. Urinary glycosaminoglycan excretion in NIDDM subjects: Its relationship to albuminura. Diabetic medicine. 1996;13(8):758-63.10.1002/(SICI)1096-9136(199608)13:8<758::AID-DIA160>3.0.CO;2-T]Search in Google Scholar
[27. Popławska-Kita A, Mierzejewska-Iwanowska B, Szelachowska M et al. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression. Diabetes Metab Res Rev 2008;24(4):310-7.10.1002/dmrr.808]Search in Google Scholar
[28. Cechowska-Pasko M, Pałka J, Bańkowski E. Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Mol Cell biochem. 1996;154(1):1-8.10.1007/BF00248454]Search in Google Scholar
[29. Juretić D, Krajnović V, Lukac-Bajalo J. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta diabetol. 2002;39(3):123-8.10.1007/s005920200030]Search in Google Scholar
[30. Harvey SJ, Miner JH. Breaking down the barrier: evidence against a role for heparan sulfate in glomerular permselectivity. J Am Soc Nephrology. 2007.10.1681/ASN.2007010086]Search in Google Scholar